Table 5.
Hazard ratios and 95% CI for the association of baseline BIA-derived measures of body fat with risk of incident, invasive female-specific cancers among women in the UK Biobank (excluding participants within two years of recruitment).
| Breast (postmenopausal)a | Endometrium | Ovary | |
|---|---|---|---|
| Multivariable-adjusted HR (95% CI) | |||
| FMI (kg/m2) | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 1.11 (0.87–1.42) | 1.38 (0.77–2.49) | 1.17 (0.69–1.97) |
| Q3 | 1.21 (0.95–1.54) | 1.03 (0.54–1.97) | 0.65 (0.35–1.21) |
| Q4 | 1.19 (0.93–1.51) | 1.52 (0.84–2.75) | 1.28 (0.76–2.15) |
| Q5 | 1.46 (1.16–1.84) | 1.35 (0.72–2.56) | 0.71 (0.38–1.33) |
| Ptrendb | 0.001 | 0.32 | 0.49 |
| Per SD increase | 1.15 (1.06–1.23) | 1.14 (0.96–1.34) | 0.98 (0.83–1.15) |
| Body fat % | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 1.05 (0.82–1.35) | 1.30 (0.72–2.34) | 0.78 (0.46–1.34) |
| Q3 | 1.23 (0.97–1.57) | 1.08 (0.57–2.04) | 0.61 (0.34–1.11) |
| Q4 | 1.23 (0.97–1.57) | 1.31 (0.70–2.45) | 1.19 (0.72–1.99) |
| Q5 | 1.33 (1.05–1.69) | 1.43 (0.76–2.69) | 0.61 (0.33–1.12) |
| Ptrendb | 0.007 | 0.33 | 0.50 |
| Per SD increase | 1.13 (1.05–1.23) | 1.13 (0.95–1.34) | 0.98 (0.83–1.16) |
| Whole body fat mass to whole body fat free mass | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 1.09 (0.85–1.40) | 1.29 (0.71–2.32) | 0.80 (0.47–1.38) |
| Q3 | 1.23 (0.97–1.57) | 0.96 (0.50–1.85) | 0.63 (0.35–1.14) |
| Q4 | 1.27 (0.99–1.62) | 1.44 (0.78–2.66) | 1.28 (0.77–2.13) |
| Q5 | 1.35 (1.06–1.71) | 1.37 (0.73–2.57) | 0.60 (0.32–1.11) |
| Ptrendb | 0.006 | 0.31 | 0.56 |
| Per SD increase | 1.13 (1.04–1.22) | 1.12 (0.95–1.32) | 0.98 (0.83–1.15) |
| BMI (kg/m2) | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 1.27 (1.01–1.61) | 0.86 (0.46–1.59) | 0.66 (0.38–1.16) |
| Q3 | 1.23 (0.97–1.56) | 1.18 (0.67–2.11) | 0.87 (0.52–1.46) |
| Q4 | 1.29 (1.02–1.64) | 0.94 (0.50–1.75) | 0.75 (0.43–1.30) |
| Q5 | 1.46 (1.16–1.84) | 1.28 (0.72–2.28) | 0.75 (0.44–1.30) |
| Ptrendb | 0.003 | 0.39 | 0.43 |
| Per SD increase | 1.12 (1.04–1.20) | 1.13 (0.96–1.33) | 0.97 (0.83–1.14) |
| TFMI (kg/m2) | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 0.98 (0.77–1.25) | 1.33 (0.72–2.43) | 0.69 (0.40–1.20) |
| Q3 | 1.16 (0.92–1.48) | 1.17 (0.62–2.24) | 0.67 (0.38–1.19) |
| Q4 | 1.07 (0.84–1.37) | 1.25 (0.65–2.39) | 1.06 (0.63–1.77) |
| Q5 | 1.47 (1.16–1.85) | 1.87 (0.99–3.50) | 0.67 (0.36–1.22) |
| Ptrendb | 0.001 | 0.10 | 0.60 |
| Per SD increase | 1.12 (0.99–1.25) | 1.16 (0.98–1.37) | 0.97 (0.82–1.14) |
| Trunk fat % | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 1.05 (0.82–1.34) | 0.90 (0.49–1.65) | 0.56 (0.31–1.01) |
| Q3 | 1.16 (0.90–1.48) | 1.01 (0.54–1.88) | 1.02 (0.60–1.73) |
| Q4 | 1.17 (0.92–1.50) | 1.16 (0.62–2.16) | 1.18 (0.70–1.99) |
| Q5 | 1.48 (1.16–1.88) | 1.59 (0.86–2.94) | 0.59 (0.31–1.13) |
| Ptrendb | 0.001 | 0.095 | 0.83 |
| Per SD increase | 1.14 (1.05–1.23) | 1.11 (0.90–1.39) | 0.97 (0.82–1.15) |
| Trunk fat mass to trunk fat free mass | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 1.00 (0.78–1.28) | 0.87 (0.47–1.61) | 0.55 (0.31–0.99) |
| Q3 | 1.16 (0.91–1.48) | 0.92 (0.49–1.74) | 0.94 (0.55–1.60) |
| Q4 | 1.15 (0.90–1.48) | 1.14 (0.61–2.14) | 1.16 (0.69–1.96) |
| Q5 | 1.43 (1.12–1.82) | 1.58 (0.86–2.91) | 0.60 (0.31–1.13) |
| Ptrendb | 0.001 | 0.090 | 0.81 |
| Per SD increase | 1.13 (1.05–1.21) | 1.14 (0.97–1.35) | 0.97 (0.82–1.14) |
| Leg fat mass (kg) | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 1.15 (0.91–1.45) | 0.78 (0.42–1.42) | 0.73 (0.43–1.23) |
| Q3 | 1.13 (0.89–1.42) | 1.13 (0.65–1.96) | 0.76 (0.45–1.28) |
| Q4 | 1.21 (0.96–1.53) | 1.03 (0.57–1.87) | 0.53 (0.29–0.99) |
| Q5 | 1.33 (1.04–1.70) | 1.09 (0.58–2.07) | 1.06 (0.60–1.85) |
| Ptrendb | 0.023 | 0.57 | 0.60 |
| Per SD increase | 1.13 (1.04–1.22) | 1.07 (0.87–1.31) | 0.94 (0.78–1.14) |
| Ratio of trunk fat mass to leg fat mass | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 1.12 (0.88–1.42) | 1.27 (0.69–2.33) | 0.46 (0.25–0.85) |
| Q3 | 1.10 (0.86–1.40) | 0.93 (0.47–1.84) | 0.86 (0.51–1.47) |
| Q4 | 0.99 (0.76–1.29) | 1.27 (0.65–2.49) | 0.96 (0.56–1.65) |
| Q5 | 1.50 (1.14–1.96) | 1.83 (0.90–3.72) | 0.72 (0.40–1.30) |
| Ptrendb | 0.025 | 0.15 | 0.99 |
| Per SD increase | 1.12 (1.02–1.22) | 1.13 (1.03–1.24) | 0.96 (0.77–1.20) |
| WC (cm) | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 0.97 (0.78–1.21) | 1.68 (0.97–2.90) | 0.58 (0.34–0.99) |
| Q3 | 1.08 (0.86–1.36) | 1.15 (0.61–2.20) | 1.13 (0.70–1.84) |
| Q4 | 1.22 (0.96–1.55) | 1.28 (0.65–2.55) | 0.81 (0.45–1.46) |
| Q5 | 1.27 (1.02–1.59) | 1.53 (0.82–2.86) | 0.62 (0.86–1.12) |
| Ptrendb | 0.006 | 0.455 | 0.36 |
| Per SD increase | 1.13 (1.05–1.22) | 1.17 (0.99–1.38) | 0.97 (0.82–1.14) |
| WHR | |||
| Q1 | 1.00 | 1.00 | 1.00 |
| Q2 | 1.10 (0.87–1.38) | 0.94 (0.52–1.70) | 1.21 (0.71–2.04) |
| Q3 | 1.08 (0.86–1.37) | 1.43 (0.83–2.48) | 0.62 (0.33–1.17) |
| Q4 | 1.09 (0.86–1.38) | 0.78 (0.41–1.50) | 1.38 (0.82–2.30) |
| Q5 | 1.24 (0.99–1.56) | 1.14 (0.62–2.08) | 0.63 (0.33–1.18) |
| Ptrendb | 0.096 | 0.860 | 0.37 |
| Per SD increase | 1.07 (0.99–1.15) | 1.14 (0.98–1.34) | 0.93 (0.79–1.10) |
All models were adjusted for age at enrollment, education, physical activity, alcohol intake, smoking, height. age at menarche, age at first full-term birth and parity combined, HRT status, age at menopause.
Ranges: FMI: ≤ 6.0, 6.1–6.9, 7.0–7.6, 7.7–8.4, >8.4; body fat %: ≤27.4, 27.5–30.5, 30.6–32.8, 32.9–35.1, >35.1; whole body fat to whole body fat free mass: ≤0.38, 0.39–0.44, 0.45–0.49, 0.50–0.54,> 0.54; BMI: ≤ 21.4, 21.5–22.6, 22.7–23.5, 23.6–24.2, >24.2; TFMI: ≤ 2.86; 2.87–3.44, 3.45–3.90, 3.91–4.39, >4.39; trunk fat %: ≤23.8, 23.9–27.8, 27.9–30.6, 30.7–33.6, >33.6; trunk fat mass to trunk fat free mass: ≤0.31, 0.32–0.38, 0.39–0.44, 0.45–0.50, >0.50; leg fat mass: ≤6.8, 6.9–7.6, 7.7–8.2, 8.3–8.8, >8.8; ratio of trunk fat mass to leg fat mass: ≤1.06, 1.07–1.19, 1.20–1.30, 1.31–1.42, >1.43; WC: ≤ 70, 71–74, 75–77, 78–80.3, >80.3; WHR: ≤ 0.74, 0.75–0.77, 0.78–0.80, 0.81–0.83, >0.83 for quintiles 1,2 3, 4 and 5, respectively.
HR hazard ratio, CI confidence interval, BMI body mass index, WC waist circumference, WHR waist to hip ratio, FMI fat mass index, TFMI trunk fat mass index.
aAlso adjusted for family history of breast cancer and mammogram ever.
bAll tests were two-sided.